Price to sales forward of Health Catalyst, Inc – NASDAQ:HCAT
This article provides the "Price to sales forward" metric for Health Catalyst, Inc (NASDAQ: HCAT). It appears to be a financial data point from TradingView, indicating the company's valuation based on future sales. The content is primarily a listing of financial and platform features from TradingView, with the core subject being HCAT's forward price-to-sales ratio.
Discover Health Catalyst And 2 More Promising Penny Stocks
This article identifies three promising penny stocks - Health Catalyst (HCAT), Resources Connection (RGP), and Mammoth Energy Services (TUSK) - highlighting their financials, growth potential, and recent developments. While all three face challenges such as unprofitability or market perception issues, they also show underlying strengths like solid revenue segments or positive financial stability indicators. The analysis emphasizes that despite the inherent risks of penny stocks, these companies offer affordability and potential when backed by fundamental data.
Price to book forward of Health Catalyst, Inc – NASDAQ:HCAT
The article discusses the forward price-to-book ratio for Health Catalyst, Inc. (NASDAQ: HCAT). It appears to be a financial data snippet from TradingView, indicating a focus on the company's valuation metric rather than providing detailed analysis. The content is sparse, highlighting the specific financial metric of Price to Book Forward.
HCAT - Health Catalyst Inc Options
This article provides a detailed financial overview of Health Catalyst Inc (HCAT), including its stock performance, key financial metrics, and company statistics. It covers market capitalization, sales, income, various ratios, employee count, IPO date, and recent insider and institutional ownership data. The company's stock closed at $2.08, up 0.48% on July 2nd.
Health Catalyst, Inc.(NasdaqGS: HCAT) dropped from Russell 2000 Value Benchmark
Health Catalyst, Inc. (NasdaqGS: HCAT) has been dropped from the Russell 2000 Value Benchmark, effective June 29, 2026. This exclusion is part of broader removals from several Russell indices, including the Russell 2000, Russell 3000E, Russell 3000, Russell 2500, and various associated Value and Dynamic benchmarks. The company recently announced the sale of Vitalware, LLC for approximately $150 million and reported Q1 2026 earnings with impairment charges.
Health Catalyst, Inc.(NasdaqGS: HCAT) dropped from Russell 2000 Index
Health Catalyst, Inc. (NasdaqGS: HCAT) has been removed from the Russell 2000 Index, as well as the Russell 2000 Value Benchmark, Russell 3000E Index, and Russell 3000 Index. This news follows several other recent developments for the company, including the sale of its Vitalware LLC subsidiary for approximately $150 million and a workforce reduction earlier in 2026. The company provides data and analytics technology and services to healthcare organizations.
Health Catalyst, Inc.(NasdaqGS: HCAT) dropped from Russell 3000E Index
Health Catalyst, Inc. (NasdaqGS: HCAT) has been dropped from the Russell 3000E Index. This news comes shortly after the company announced its agreement to sell Vitalware, LLC for approximately $150 million, and also reported its Q1 2026 earnings with impairment charges and a workforce reduction. Health Catalyst provides data and analytics technology and services to healthcare organizations.
Health Catalyst Inc (HCAT) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Health Catalyst Inc (HCAT), focusing on its support and resistance levels, price momentum, and various technical indicators and moving averages. HCAT's current price momentum is 7.09, suggesting range-bound swing trading between resistance at $2.33 and support at $1.38. Technical indicators suggest a "Buy" signal for HCAT, with strong buy signals from moving averages.
HCAT Maintained by Wells Fargo -- Price Target Raised to $1.75
Wells Fargo analyst Stan Berenshteyn has maintained an "Equal-Weight" rating for Health Catalyst (HCAT) and raised the price target to $1.75 from $1.00, a 75% increase. Despite this positive adjustment, Health Catalyst's GF Score™ is 49/100, indicating moderate potential but also challenges in profitability and valuation, even as its GF Value™ suggests it is currently 62.9% undervalued. The article highlights the company's position in healthcare data and analytics but also points to its financial strength concerns.
Health Catalyst Inc (HCAT) Financial Health: Profitability & Balance Sheet Analysis
Health Catalyst Inc (HCAT) currently has a weak financial status with a financial score of 6.67 out of 487 in the Software & IT Services industry. The company's latest quarterly revenue decreased by 10.90% year-over-year to $70.76M, and its net profit saw a significant decrease of 367.64% year-over-year. While its operating efficiency is noted as high, specific financial data for various metrics like cash and cash equivalents, total assets, operating profit, and free cash flow have not been disclosed by the company yet.
Data Analytics Stocks Q1 Highlights: Health Catalyst (NASDAQ:HCAT)
This article provides a Q1 earnings overview for several data analytics companies, highlighting Health Catalyst (HCAT) as having solid results but with weakest guidance updates. It contrasts HCAT's performance with Palantir Technologies (PLTR) which showed strong revenue growth, and Domo (DOMO) which reported flat revenues and missed analyst expectations. The piece also briefly touches on Strategy (MSTR) and CLEAR Secure (YOU) and their Q1 performances.
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know
Shares of Health Catalyst, Zoom, and Autodesk declined following widespread fears that AI agents could erode traditional enterprise software subscription models, further compounded by high-profile AI talent departures and regulatory overhangs. The market is pricing in significant cannibalization from AI, even as some companies like Salesforce show strong AI revenue lines and share buybacks. The article suggests these price drops could present buying opportunities for high-quality stocks.
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know
Shares of Health Catalyst (HCAT), Zoom (ZM), and Autodesk (ADSK) experienced declines due to a general downturn in the communication services and software sector. This decline was triggered by AI talent departures from Alphabet and broader market fears that AI agents could erode the traditional subscription model of enterprise software. Despite mixed signals from company performance and analyst upgrades, the market remains cautious about the software sector until AI revenue growth demonstrably outpaces potential cannibalization of legacy services.
Palogic reports 6.7% Health Catalyst (HCAT) stake and outlines possible actions
Palogic-related entities and Ryan L. Vardeman have disclosed a beneficial ownership of 6.7% in Health Catalyst (HCAT), totaling 4,918,866 shares acquired for approximately $11 million. While stating the investment is for ordinary purposes, the filing outlines potential future actions including share purchases/sales and involvement in strategic or governance changes. Palogic has expressed support for Health Catalyst's new CEO and the divestiture of VitalWare.
Health Catalyst, Zoom, and Autodesk Shares Are Falling, What You Need To Know
Shares of Health Catalyst, Zoom, and Autodesk declined following a broader market downturn affecting communication services and softwarecomplexes. This decline was attributed to AI talent departures, regulatory overhang, and persistent market fears that AI agents will erode traditional subscription models in enterprise software. The market's reaction, despite some strong company fundamentals, suggests a cautious outlook until AI revenue clearly outpaces the erosion of legacy subscriptions.
Ryan L. Vardeman discloses investment at Health Catalyst with 6.7% stake
Ryan L. Vardeman, through Palogic-affiliated entities, has acquired a 6.7% stake in Health Catalyst, Inc. common stock, crossing the reporting threshold on June 12, 2026. The filing indicates plans for active engagement with Health Catalyst's management and board, expressing support for new leadership and a recent divestiture. Palogic, led by Ryan L. Vardeman, focuses on long-term investing and aims to improve value through engagement with companies.
Health Catalyst Inc (HCAT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Health Catalyst Inc (HCAT) has an earnings forecast score of 6.75, ranking 334 out of 489 in its industry. Analysts have an average price target of $4.00, with a consensus "Hold" rating based on 7 analysts. The company's expected revenue for the next quarter is $68.97M, with an anticipated EPS of $0.03.
Health Catalyst to Participate in Upcoming Investor Conference
Health Catalyst, Inc. announced its participation in the Truist Securities Healthcare Disruptors & Digital Health Conference. Senior management members will attend, with CEO Ben Albert participating in a panel discussion on "AI ROI in Healthcare: Real vs Hype Debate" on June 24, 2026. Health Catalyst is a healthcare intelligence company focused on accelerating improvement for health systems through AI-driven technology.
Health Catalyst to Participate in Upcoming Investor Conference
Health Catalyst, Inc. (Nasdaq: HCAT) announced that its senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference. CEO Ben Albert will be part of a panel discussion on "AI ROI in Healthcare: Real vs Hype Debate" on June 24, 2026, at 3:30 pm ET. The company aims to accelerate measurable improvement for health systems through its healthcare intelligence solutions.
Health Catalyst and Paycom Shares Are Falling, What You Need To Know
Shares of Health Catalyst (HCAT) and Paycom (PAYC) fell significantly due to investor rotation out of high-multiple growth stocks, driven by rising inflation expectations and geopolitical tensions. The market is increasingly sensitive to AI development, with new efficient AI agents challenging the business model of per-seat enterprise software subscriptions. Health Catalyst, in particular, is down 23% year-to-date and 57.1% below its 52-week high.
Health Catalyst and Paycom Shares Are Falling, What You Need To Know
Shares of Health Catalyst (HCAT) and Paycom (PAYC) experienced drops following a market rotation away from high-multiple growth stocks. This shift was influenced by higher-than-expected May import price data, suggesting persistent inflation, and investor caution ahead of a Federal Reserve meeting. The market also reacted to a Bank of America survey highlighting an "AI bubble" as a major tail risk and SpaceX's acquisition of AI coding platform Cursor, signaling consolidation in the AI software sector.
AI ROI: real vs hype in healthcare, Health Catalyst CEO on June 24 panel
Health Catalyst (HCAT) announced that its CEO, Ben Albert, will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference on June 24, 2026. Albert will join a panel discussion titled “AI ROI in Healthcare: Real vs Hype Debate” at 3:30 PM ET. The company, a healthcare intelligence provider, emphasizes its role in accelerating measurable improvements for health systems through AI-driven technology.
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst announced its definitive agreement to divest Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on its core technology and AI investments for driving measurable improvement in healthcare, while strengthening its balance sheet. The net proceeds from the sale are intended to repay and terminate its existing senior secured term loan facility of approximately $160 million.
Health Catalyst (HCAT) CEO uses 34,485 shares to cover RSU tax bill
Health Catalyst (HCAT) CEO Albert Benjamin disposed of 34,485 shares of common stock at an average price of $1.6918 per share. This "sell to cover" transaction was mandated to satisfy tax withholding obligations related to the vesting of his restricted stock units and was not a discretionary sale. Following this transaction, Benjamin directly holds 1,423,971 shares of Health Catalyst.
Health Catalyst (HCAT) Form 144: 34,485 restricted shares planned sale 06/10/2026
Health Catalyst, Inc. (HCAT) has filed a Form 144 indicating a proposed sale of 34,485 restricted shares of Common Stock, sourced from compensation, with an intended sale date of June 10, 2026. The filing also notes prior restricted stock sales by the same holder on March 10, May 1, and June 1, 2026. This SEC filing serves as a transparency measure for the market regarding insider trading.
Health Catalyst stock (US42226A1079): shares move after fresh Goldman Sachs healthcare conference vi
Health Catalyst (HCAT) stock has garnered investor attention following its presentation at the Goldman Sachs Global Healthcare Conference and its Q1 2026 earnings report, which indicated continued revenue growth and a narrowing net loss. The company, which specializes in healthcare data analytics, saw noticeable intraday stock swings as investors processed updated guidance. Its business model focuses on providing cloud-based data platforms and analytics applications to healthcare organizations, aiming to improve clinical, financial, and operational performance.
Health Catalyst, Tenable, and Pegasystems Stocks Trade Down, What You Need To Know
Health Catalyst, Tenable, and Pegasystems stocks experienced a downturn following the release of new AI models by Anthropic, Claude Fable 5 and Claude Mythos 5, which are designed for complex knowledge work and coding problems. This development reinforced the "SaaSpocalypse" thesis, suggesting that more capable AI agents could reduce the need for expensive enterprise software subscriptions. The market weakness was further exacerbated by geopolitical concerns, including an American Apache helicopter incident near Oman and comments from Donald Trump regarding a potential Iranian attack, contributing to a macro headwind for long-duration software assets due to possible sustained higher interest rates.
Health Catalyst to Cut 9% of Workforce
Health Catalyst (HCAT) announced it will cut 9% of its workforce as part of a restructuring plan aimed at improving operational efficiency. The company expects to incur approximately $5.0 million in severance costs, with most of these expenses recognized in the second quarter of 2026. This move aligns with its broader financial goals to optimize operations and achieve profitability.
Whetstone updates Health Catalyst (HCAT) ownership to 4.5% stake
Whetstone Capital Advisors and David Atterbury have filed an updated Schedule 13D/A, disclosing a 4.5% beneficial ownership stake in Health Catalyst (HCAT). This stake amounts to 3,285,690 shares, including common stock and shares underlying long call options, and was acquired using approximately $7.83 million in working capital from the funds they advise. The filing indicates shared voting and dispositive power over these shares, with long and short options expiring in December 2026.
Med-Metrix Acquires Vitalware from Publicly Traded Health Catalyst
Med-Metrix, a revenue cycle management platform backed by Harvest Partners and A&M Capital Partners, has acquired Vitalware from Health Catalyst for $147 million in cash. Vitalware provides cloud-based revenue integrity and chargemaster management software for hospitals and health systems. This acquisition enhances Med-Metrix's services by adding mid-revenue cycle software capabilities, aligning with its strategy of combining operator-led services with scalable software.
Health Catalyst to Divest Vitalware Unit to Med-Metrix for $147M
Health Catalyst has signed a definitive agreement to sell its Vitalware LLC unit to Med-Metrix for $147 million in cash. This strategic divestiture allows Health Catalyst to exit a non-core financial software segment and focus on its primary clinical, operational, and consumer performance improvement technologies. The proceeds will be used to repay its $160 million senior secured term loan facility, improving its balance sheet and redirecting focus to its core data platform and AI roadmap.
Health Catalyst Company Profile & Introduction
This document provides a company profile and introduction for Health Catalyst. It describes the company's core business, history, and key offerings in the healthcare technology sector. The profile aims to give readers a comprehensive overview of Health Catalyst's role in improving healthcare outcomes through data analytics and technology.
Health Catalyst Inc (HCAT) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live stock quotes and charts for Health Catalyst Inc (HCAT), showing its current stock price and daily performance. It indicates that there are no analyst ratings or earnings information currently available for HCAT. The page also includes promotional content for trading alerts and options strategies.
Weekly Rundown: Trump signs AI executive order; Health Catalyst to sell Vitalware for $147M
This weekly rundown covers several key developments in health tech, including President Trump signing an executive order to bolster AI-enabled cybersecurity, particularly benefiting rural hospitals. Health Catalyst announced its divestiture of Vitalware for $147 million to sharpen its focus on core AI-driven improvements. Additionally, both Vida Health and Instacart are partnering to expand access to nutritious food, and new data suggests AI tools are greatly influencing patient choices for healthcare providers.
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst announced its definitive agreement to divest its Vitalware business unit to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on AI and core technology, strengthen its balance sheet, and provide financial flexibility by repaying its existing senior secured term loan. Med-Metrix, a revenue cycle management company, is well-positioned to further invest in Vitalware, which generated approximately $37 million in fiscal year 2025 revenue.
Health Catalyst to Divest Vitalware Unit for $147M to Med-Metrix
Health Catalyst has announced the divestiture of its Vitalware mid-revenue cycle business unit to Med-Metrix for $147 million in cash. This strategic move aims to streamline Health Catalyst's operations, pay off outstanding debt, and intensify its focus on core clinical transformation and AI roadmap. Vitalware, which generated $37 million in revenue in fiscal year 2025, will now be managed by a company dedicated to revenue cycle management, while Health Catalyst utilizes the capital to aggressively fund its specialized artificial intelligence frameworks.
Med-Metrix, LLC entered into a definitive agreement to acquire Vitalware, LLC from Health Catalyst, Inc..
Med-Metrix, LLC has agreed to acquire Vitalware, LLC from Health Catalyst, Inc. for $147 million in cash. Health Catalyst plans to use the net proceeds, along with cash on hand, to repay and terminate its existing senior secured term loan facility. The transaction is subject to regulatory approvals and employment offers for Vitalware employees, with an expected closing in the third quarter of 2026.
Latham & Watkins Advises Health Catalyst on Divestiture of Vitalware
Latham & Watkins LLP advised Health Catalyst, Inc. on its definitive agreement to divest Vitalware, LLC and its mid-revenue cycle business to Med-Metrix. This divestiture aims to sharpen Health Catalyst's focus on improving cost, clinical, and consumer performance for health systems and accelerate its broader strategic transformation. A multidisciplinary Latham & Watkins team led by Bay Area partner Tessa Bernhardt represented Health Catalyst in the transaction.
Health Catalyst jumps on announcement to sell Vitalware to Med‑Metrix for $147M
Health Catalyst (HCAT) announced its plans to sell its Vitalware business to Med-Metrix for $147 million in cash. This strategic divestiture, expected to close in Q3, will allow Health Catalyst to focus on its core data and analytics business, enhance profitability, and potentially accelerate share repurchases. The news led to a significant jump in Health Catalyst's stock price during after-hours trading.
Health Catalyst (HCAT) Divests Vitalware for $147 Million
Health Catalyst Inc. (HCAT) has announced the divestiture of its Vitalware business unit to Med-Metrix for $147 million in cash, a strategic move to streamline operations and enhance focus on core business areas. Despite this, the company faces significant weaknesses in financial strength and profitability, as indicated by its GF Score™ of 46/100, alongside insider selling activity totaling over $245,000. Investors are advised to exercise caution due to these factors, even with a low price-to-sales ratio suggesting potential undervaluation.
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst (Nasdaq: HCAT) has signed a definitive agreement to divest its mid-revenue cycle business unit, Vitalware, to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on AI and core technology, strengthening its balance sheet and providing financial flexibility. The proceeds will be used to repay and terminate its existing senior secured term loan facility.
HCAT Stock Jumps As Strategic Reset Follows Earnings Beat
Health Catalyst Inc. (HCAT) stock jumped 38.17% after beating Q1 2026 earnings expectations and announcing a strategic operating model reset. The company reported adjusted EPS of $0.02 and revenue of $70.76M, though Q1 still saw an 11% year-over-year revenue decline and a significant goodwill impairment. The strategic shift focuses on its Ignite platform, prioritizing profitability and cash flow over top-line growth,
Health Catalyst to sell Vitalware unit for $147 million cash
Health Catalyst Inc. announced it would sell its Vitalware LLC unit to Med-Metrix for $147 million in cash. The company plans to use the proceeds, along with cash on hand, to fully repay its existing senior secured term loan facility of approximately $160 million. This strategic move aims to refocus Health Catalyst on its core technology and AI investments, with analysts predicting profitability this year.
Health Catalyst (NASDAQ: HCAT) divests Vitalware to repay term loan debt
Health Catalyst (NASDAQ: HCAT) has announced the divestiture of its Vitalware business unit to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on its core data, technology, and AI offerings. The net proceeds from the sale, combined with cash on hand, will be used to fully repay and terminate the company's senior secured term loan facility, which had approximately $160 million of outstanding principal. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and other closing conditions.
Health Catalyst to Sell Vitalware Business to Med-Metrix for $147 Million, Repay Term Loan
Health Catalyst (HCAT) has entered into an agreement to sell its Vitalware business to Med-Metrix for a base price of $147 million. The company intends to use the net proceeds, along with cash on hand, to repay and terminate its existing senior secured term loan. The closing of the transaction is anticipated in Q3 2026, subject to customary conditions.
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst, Inc. announced its definitive agreement to divest its mid-revenue cycle business unit, Vitalware, to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on AI and core technology, strengthening its balance sheet and providing financial flexibility. The proceeds will be used to fully repay its existing senior secured term loan facility of approximately $160 million.
Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation
Health Catalyst (Nasdaq: HCAT) announced its divestiture of Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 million in cash. This strategic move aims to sharpen Health Catalyst's focus on AI and its core technology, strengthening its balance sheet and providing financial flexibility for future investments. The net proceeds will be used to fully repay its existing senior secured term loan facility of approximately $160 million.
Selling a side business, Health Catalyst plans to pay off $160M loan
Health Catalyst (HCAT) has signed an agreement to sell its Vitalware business unit to Med-Metrix for $147 million in cash. The company intends to use the proceeds, combined with cash on hand, to fully repay and terminate its approximately $160 million senior secured term loan. This divestiture aims to strengthen Health Catalyst's balance sheet, increase financial flexibility, and sharpen its focus on core technology and AI-driven healthcare improvement.
Health Catalyst (HCAT) General Counsel sells shares to cover RSU tax withholding
Health Catalyst, Inc.'s General Counsel, Benjamin Landry, reported a mandatory sale of 13,779 shares of common stock at $1.3702 per share on June 1, 2026. This "sell to cover" transaction was required to satisfy tax withholding obligations arising from the vesting of restricted stock units. Following this, Landry holds 364,539 shares of Health Catalyst common stock.
Health Catalyst (HCAT) CFO mandated share sale to cover RSU taxes
Health Catalyst, Inc. CFO Jason Alger sold 18,804 shares of common stock at $1.3702 per share to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). This "sell to cover" transaction was mandated by the company's equity incentive plans and was not a discretionary trade. Following this transaction, Alger directly holds 722,840 common shares of HCAT.
